Table 1.
Matrigel Transmigration Analyses of Myopodin-Transformed PC-3 and LNCaP Cells*
| Cell ratios | Cells invading through Matrigel HPF† | Cells in control membrane HPF | Invasion/migration |
|---|---|---|---|
| PC-3 + pCMV | |||
| Clone P1 | 28.2 ± 2.5 | 43.4 ± 5.1 | 0.65 |
| Clone P2 | 20.6 ± 1.4 | 25.5 ± 2.3 | 0.82 |
| Clone P3 | 18.4 ± 1.6 | 24.9 ± 2.9 | 0.74 |
| PC-3 + pCMV-myopodin | |||
| Clone I1 | 5.2 ± 1 | 37.5 ± 5.4 | 0.14 |
| Clone I2 | 5.6 ± 1.3 | 29.4 ± 2.7 | 0.19 |
| Clone I8 | 3.0 ± 0.9 | 27.2 ± 2.5 | 0.11 |
| Clone I4 | 3.8 ± 2.2 | 29.2 ± 3.1 | 0.13 |
| Clone I4 + anti-sense | 25.5 ± 5.1 | 35.6 ± 3.8 | 0.71 |
| Clone I4 + sense | 5.2 ± 2.1 | 24.8 ± 4.2 | 0.21 |
| PC-3 + pCMV-myopo5.9‡ | |||
| Clone 5.9 no. 8 | 30.6 ± 5.6 | 48.3 ± 6.3 | 0.63 |
| Clone 5.9 no. 10 | 24.7 ± 6.1 | 40.6 ± 7.2 | 0.61 |
| PC-3 + pCMV-myopo5.0§ | |||
| Clone 5.0 no. 3 | 28.3 ± 3.2 | 35.2 ± 5.9 | 0.80 |
| Clone 5.0 no. 12 | 23.5 ± 4.4 | 32.6 ± 3.7 | 0.72 |
| LNCaP + pCMV | |||
| Clone LP2 | 34.1 ± 5.2 | 48.2 ± 6.3 | 0.70 |
| Clone LP6 | 33.8 ± 7.1 | 66.3 ± 8.2 | 0.51 |
| LNCaP + pCMV-myopodin | |||
| Clone LM9 | 7.8 ± 1.2 | 68.4 ± 6.7 | 0.11 |
| Clone LM25 | 3.4 ± 0.7 | 78.7 ± 9.2 | 0.04 |
*
The pCMV-transformed PC-3 and LNCaP cells and their myopodin-transformed counterparts will be suspended in DMEM containing 0.1% bovine serum albumin and added to the upper chamber at 1 × 105 cells/insert. The inserts contained an 8-μm pore-size membrane with a thin layer of Matrigel basement membrane matrix. Controls were those containing basement membrane but no insert in the chamber.
†
Mean of five experiments with standard errors. HPF-per high-power field.
‡
Myopodin expression vector with partial deletion of synaptopodin homologous sequence.
§
Myopodin expression vector with complete deletion of synaptopodin homologous sequence.